

Materials for this course will release 11/15/2022

Cardiology Self-Assessment Program (CardSAP) Book 2: Special Population (Cert # L229389)

Teaser: This Self-Assessment Program series provides Cardiology pharmacists with pertinent therapeutic updates to enhance their practice skills and improve patient outcomes.

Tag: Certifications; Cardiology



ACPE Numbers: Various – see listing below

Pre-Sale Date: 10/12/2022

Release Date: 11/15/2022

Expiration Dates: 05/15/2023

Activity Type: Application-based

CE Credits: TBD contact hours (BPS and ACPE)

Activity Fee: \$80 (ASHP member); \$120 (non-member)

Accreditation for Pharmacists



The American College of Clinical Pharmacy and American Society of Health-System Pharmacists are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

Target Audience

The target audience for Cardiology Self-Assessment Program (CardSAP) Book 2: Special Population is board-certified cardiology pharmacy specialists caring for patients who have developed cardiac arrhythmias and/or thromboembolic disorders.

Activity Overview

This course is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). The course consists of 3 learning modules (see table below) and provides up to TBD contact hours of continuing pharmacy education and/or recertification credit.

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.

These activities are part of the ACCP and ASHP professional development program for BCCP recertification approved by the BPS.

Recertification Credit*

Board certified pharmacists are eligible to receive up to TBD contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Materials for this course will release 11/15/2022

Learning Activity	ACPE Number	Contact Hours	Assessment Pass Point
Special Populations I	TBD	TBD	TBD
Special Populations II	TBD	TBD	TBD
Special Populations III	TBD	TBD	TBD
		TBD BPS	

LEARNING OBJECTIVES

Special Populations I

ACPE #:

Chapter: Substance Use and Cardiovascular Disease

- Evaluate current trends within the United States regarding substance use, and using current diagnostic criteria, distinguish among specific substance use disorders.
- Distinguish current state and national health policy regulations regarding medicinal or recreational cannabis use, and delineate the FDA’s role in regulating cannabis products.
- Given a patient with or without underlying cardiovascular disease (CVD) who is using cannabis, evaluate for specific cannabinoid-drug interactions, and devise a therapeutic plan to mitigate potential cardiac adverse effects.
- Given a patient with or without underlying CVD who is misusing cannabis, opiates, or stimulants, evaluate for specific acute and chronic CV complications, and devise a therapeutic plan to mitigate or treat these complications.
- Identify emerging substances of misuse, and estimate potential acute and chronic CV complications using electronic data resources.
- Design appropriate education for patients and health care providers regarding the legal and CV issues surrounding substance use, particularly cannabis use.

Chapter: Disparities in Cardiovascular Therapeutics

- Evaluate the quality of cardiovascular (CV) care among patients experiencing health care disparities.
- Identify populations at highest risk of health care disparities in CV disease (CVD) care.
- Assess the impact of CVD on patients experiencing health care disparities.
- Justify current practice innovations to decrease the gap in health care disparities for populations at high risk of CVD.
- Develop practice-changing approaches to caring for patients experiencing health care disparities.
- Design clinical services to address health care disparities using existing tools and strategies.

Special Populations II

ACPE #:

Chapter: Pregnancy and Cardiovascular Disease

- Distinguish key physiologic changes that occur during pregnancy that increase a patient’s cardiovascular (CV) risk.
- Assess a patient’s signs and symptoms and medical history to differentiate CV risks of concern from normal signs and symptoms of pregnancy.
- Design a complete treatment plan for a pregnant patient who also has a CV condition, considering maternal and fetal risks regarding medication management, potential complications, monitoring recommendations, and pharmacologic therapy.
- Analyze short- and long-term risks after delivery associated with CV conditions during pregnancy.
- Design preventive care for patients with a history of a CV condition during pregnancy.

Materials for this course will release 11/15/2022

Chapter: Congenital Heart Disease in Adults

- Distinguish the physiologic differences of congenital heart defects compared with the anatomically normal heart.
- Design a comprehensive therapeutic drug plan to address commonly encountered complications in adults with congenital heart defects.
- Apply the special considerations for creating a comprehensive therapeutic drug plan in adults with congenital heart disease.

Chapter: Cardiovascular Disease in Patients with Cancer

- Evaluate patients for the most common cancer treatment-induced cardiotoxicity.
- Assess a patient's baseline cardiovascular risk to judge when to withhold cancer therapy.
- Develop a plan to prevent, diagnose, and manage cardiotoxicity.
- Demonstrate application of the recommendations of the 2022 ESC guideline for cardio-oncology.

Special Populations III

ACPE #:

Interactive Case: Obesity and Cardiovascular Disease

- Distinguish obesity-related criteria and cardiovascular risk considerations for obesity.
- Evaluate nonpharmacologic therapies for obesity including diet and physical activity.
- Evaluate current FDA-approved medications for weight loss.
- Assess evidence of weight-loss drugs in patients with or at risk for cardiovascular disease.
- Evaluate strategies for parenteral anticoagulant dosing in obesity.

Interactive Case: Deprescribing in Cardiovascular Disease

- Demonstrate the concept of deprescribing and how it pertains to the management of cardiovascular disease.
- Apply evidence for the use of aspirin to prevent cardiovascular events in patients without a history of cardiovascular disease.
- Distinguish between differences in the minimum recommended duration of therapy for dual antiplatelet therapy in patients with coronary artery disease.
- Develop an approach to discontinuing statin therapy in older adults with advanced age with or without frailty.
- Evaluate the evidence for statin therapy in patients with moderate-to-severe chronic kidney disease not requiring dialysis.
- Evaluate the evidence for statin therapy in patients with end-stage renal disease.
- Assess the evidence to support discontinuation of beta-blockers in patients post-myocardial infarction in the absence of angina or left ventricular dysfunction.
- Evaluate the evidence to support discontinuing amiodarone in patients with atrial fibrillation post-cardiac surgery.

Disclosures

In accordance with our accreditor's Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

Materials for this course will release 11/15/2022

TBD

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Methods and CE Requirements

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

- Complete the attestation statement
- Review all content
- Complete and pass the assessments
- Complete the evaluations

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites.

View the [minimum technical and system requirements](#) for learning activities.

Development

ACCP and ASHP collaborate on cardiology pharmacy activities.